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BACKGROUND: 13-Cis retinoic acid (13-CRA) is a synthetic vitamin A derivative. High-dose 13-CRA in patients with squamous cell
cancers of the head and neck (SCCHNs) reduces the incidence of second primary tumors (SPTs). The authors report long-term results
from a phase 3 randomized trial that compared treatment with low-dose 13-CRA versus placebo for patients who had early stage
SCCHN, with a focus on the development of SPTs and overall survival (OS). METHODS: In total, 176 patients who received treatment
for stage I/II SCCHN were randomized to receive either low-dose 13-CRA (weight-based dose of 7.5mg or 10mg) or placebo for 2
years. A competing-risk approach and the log-rank test were used to compare the time to SPT and OS, respectively, between groups.
RESULTS: 13-CRA neither significantly reduced the cumulative incidence of SPT (P5.61) nor improved the time to SPT (hazard ratio
[HR] for 13-CRA/placebo; 0.86; P5.61). Despite limited power, there was a trend toward improved OS for the 13-CRA arm (HR, 0.75;
P5.14), particularly among patients whose index tumor was surgically excised (N526; HR, 0.50; P5.057) and among women
(N539; HR, 0.44; P5.065) and never/former smokers (N5 129; HR, 0.61; P5.055), with a median follow-up of 16 years. The main 13-
CRA related toxicities were dry skin and cheilitis. CONCLUSIONS: Treatment with low-dose 13-CRA for 2 years did not decrease the
incidence of SPT; subset analysis indicates a potential survival advantage among patients who are women and never/former smokers.
More targeted interventions based on clinical risk factors and molecular characterization of tumors may yield greater success in
future prevention trials. Cancer 2017;123:4653-62. VC 2017 American Cancer Society.
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INTRODUCTION
Over 60,000 cases of head and neck cancers are diagnosed annually in the United States, and approximately 13,000
patients die of their disease.1 Squamous cell cancers (SSCs) of the head and neck (SCCHNs) remain among the top 10
causes of new cancer cases in men.1 Although recent decades have witnessed significant improvements in overall survival
(OS) for patients diagnosed with early stage (stage I-II) SCCHN, the risk of developing second primary tumors (SPTs)
remains significantly increased compared with an age-matched general population2,3 and is a major cause of increased
morbidity and mortality among survivors of early stage SCCHN.4-6
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Vitamin A and its synthetic analogs (retinoids) are
potent agents for the control of cell differentiation and
prevention of carcinogenesis in normal and preneoplastic
epithelial cells.7 Sporn et al demonstrated the efficacy of
retinoids in reversing premalignant lesions in mouse mod-
els.7 Hong et al reported that a 1 or 2mg/kg daily dose of
13-cisretinoic acid (13-CRA [isotretinoin]) given to
patients with oral leukoplakia significantly decreased the
size of their lesions and completely reversed dysplasia in
54% of patients.8 Relapse occurred in greater than one-
half of responders from 2 to 3 months after drug cessa-
tion.8 The authors then randomized 103 patients who
had received curative treatment for stage I through IV
SCCHN to daily, high-dose 13-CRA (50-100mg/m2
body surface area) versus placebo for 12 months.9
Although there were no significant differences in local or
distant recurrence, the intervention arm had significantly
fewer SPTs (4% vs 24%; P5 .005). However, isotreti-
noin did not prolong OS,10 but majority of patients in
both arms remained alive. Toxicities of skin dryness, chei-
litis, hypertriglyceridemia, and conjunctivitis proved
dose-limiting.9
A subsequent European trial used etretinate, a
second-generation retinoid, in the postsurgery/radiation
setting for patients with stage I through III SCCs of the
oral cavity and oropharynx.11 At a median follow-up of
41 months, there was no significant difference in SPTs
between groups, whereas patients in the treatment arm
experienced significantly greater toxicity (33% vs 23%;
P< .05).
The largest intervention trial in patients who
received curative treatment for stage I and II SCCHN
accrued at the same time as our trial.12 Given the high tox-
icity rate with the 50 to 100mg/m2 body surface area
dose, a lower daily dose of isotretinoin (30mg) or placebo
was received for a longer duration (3 years). Patients were
monitored for 4 years beyond treatment completion, and
there were no significant differences in SPTs or OS
between arms. Considerable toxicity was reported even at
this lower dose, with nearly 30% of patients requiring
dose reduction or treatment discontinuation.
The Eastern Cooperative Oncology Group
(ECOG)-ACRIN Research Group trial C0590 tested the
lowest dose of isotretinoin ever used in this setting. Here,
we report the longest follow-up to date of the effects of a
retinoid in preventing SPTs in patients with SCCHN.
C0590 was designed with 2 objectives: 1) to confirm
that treatment with 13-CRA was more effective than pla-
cebo in preventing SPTs in SCCHN survivors; and 2) to
determine whether lower, weight-based daily dosing
(7.5mg for patients who weighed <60 kg and 10mg for
those who weighed>60 kg) over 2 years would have simi-
lar efficacy while improving tolerability and compliance.
We also evaluated the association between smoking his-
tory and SPT development.
MATERIALS AND METHODS
This was a multicenter, randomized, placebo-controlled,
double-blind phase 3 intergroup trial coordinated by the
ECOG-ACRIN Cancer Research Group. Affiliated Radi-
ation Therapy Oncology Group and North Central Can-
cer Treatment Group institutions also accrued to the
study. However, the Radiation Therapy Oncology Group
discontinued recruitment from July 1991. This study was
approved by institutional review boards of all participat-
ing institutions and cooperative groups.
Patient Eligibility
Eligibility criteria included: histologically proven, stage I/
II SCC of the oral cavity, oropharynx, hypopharynx, or
larynx; an ECOG performance status of 0 or 1; chest and
bone x-rays within 35 days after definitive treatment,
before randomization; hematology and chemistries within
2 weeks before randomization; adequate bone marrow,
renal, and hepatic function (hemoglobin 10 g/dL, white
blood count >3000/mm3, platelet count> 100,000/
mm3; transaminases 1.5 times the upper limit of nor-
mal; serum creatinine 1.5 times the upper limit of nor-
mal; and electrolytes within normal limits); no treatment
for hyperlipidemia; no symptomatic coronary arterioscle-
rotic disease or prior history of coronary bypass surgery;
completion of primary therapy with surgery and/or radia-
tion within 730 days before randomization; and no evi-
dence of disease. In addition, patients had to be capable of
providing written informed consent in compliance with
institutional and federal guidelines and had to be available
for long-term follow-up.
Exclusion criteria included: prior chemotherapy;
other concurrent malignancies, except for localized and
resected nonmelanoma skin cancer; pregnancy; and lacta-
tion. Women of childbearing potential had to agree to use
contraception and to have a negative pregnancy test before
study initiation.
Study Design and Target Accrual
Sample-size calculation was based on an exponential cure-
rate model, as proposed by Berkson and Gage,13 with pre-
dicted rates of freedom from SPT of 80% and 90% for
the placebo and 13-CRA arms, respectively. The design
specified a log-rank test at the 1-sided significance level of
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.05 to compare the treatment and placebo groups. The
accrual goal was 275 cases. Under the assumptions of the
design, 5.5 years of accrual at 50 patients per year and 2.2
years of follow-up would yield 80% power, at a 1-sided
significance level of .05. Because of a lower than expected
accrual rate, the study did not meet its design specifica-
tions and was terminated on January 15, 1999. The last
patient was randomized on January 12, 1999.
Treatment Plan
Patients were randomized equally to receive treatment
(13-CRA) or placebo by using permuted blocks within
strata. Stratification factors used were: disease site (oral
cavity, hypopharynx, oropharynx, larynx), smoking his-
tory (never-smokers vs former smokers vs current smok-
ers), alcohol history (never-drinkers vs former drinkers vs
current drinkers), and weight in kilograms (<60 kg
vs> 60 kg).
In the treatment group, 13-CRA was dispensed in
3.75-mg and 5-mg gelatin capsules, depending on patient
weight. Placebo was dispensed in identical capsules and
dosages. Patients took 2 capsules once daily at bedtime.
This was a double-blind study, and treatment began
within 10 days of randomization. In the event of an emer-
gency or severe adverse reaction, unblinding of the medi-
cation would take place.
Therapy would continue daily for a total of 2 years
or until patients developed limiting toxicities or SPTs.
According to the protocol, follow-up assessments would
be administered at 1 month after study entry and then
every 6 months until 5 years post-treatment.
Endpoints
The major objective of this study was to compare the
effectiveness of 13-CRA treatment versus placebo in
patients with SCCHN who had a high probability of cure
from their primary cancer. Primary endpoints included
the number of SPTs and the time to diagnosis of an SPT
(TSP). Secondary endpoints were OS and toxicity.
Statistical Methods
Descriptive statistics were used to summarize patient
demographic and disease characteristics. Fisher exact tests
and Wilcoxon 2-sample tests were used to compare the
distribution of frequency data and continuous data
between groups, as appropriate. TSP was defined as the
time from randomization to the occurrence of an SPT.
Patients who remained alive without reporting an SPT
were censored at date of last contact. Cumulative inci-
dence rates of SPT and associated 95% confidence
intervals (CIs) were constructed and compared using the
method of Gray14 by considering death without SPT as a
competing risk. OS was measured from randomization to
the date of all-cause death and was censored at date of last
contact. OS distributions were estimated using the
Kaplan-Meier method15 and were compared using the
log-rank test.16 A Cox proportional-hazards model17 and
competing-risk regression model18 also were used to esti-
mate associations between time-to-event and covariates of
interest. The P values reported are 2-sided.
RESULTS
In total, 189 patients who received previous treatment for
stage I/II SCC of the oral cavity, oropharynx, hypophar-
ynx, or larynx, were enrolled between 1989 and January
1999, with an overall accrual rate of 26 patients per year.
The Consolidated Standards of Reporting Trials (CON-
SORT) diagram (Fig. 1) illustrates the number of patients
assigned to each arm. By using an intent-to-treat and
excluding ineligible patients, the total number of evalu-
able patients was 176, with 91 assigned to the 13-CRA
group and 85 assigned to the placebo group.
The first interim analysis was performed in Novem-
ber 1998. No significant differences in the SPT rate were
noted between arms. Given slow accrual, the data safety
monitoring committee recommended closing the study to
further registration.
Study follow-up was terminated in April 2015. At
the time of this analysis, 108 patients had died (61%; 53
in the 13-CRA arm and 55 in the placebo arm). Thirty-
one patients were lost to or refused follow-up (18%; 15 in
the 13-CRA arm and 16 in the placebo arm). Among 61
patients who had cause-of-death information submitted,
38% died from SCCHN, and 62% of deaths were neither
treatment-related nor disease-related. The median follow-
up for survivors was 16.1 years (range, 1.0-25.5 years).
Patient Characteristics
Table 1 provides the demographics for 176 randomly
assigned eligible patients. Distributions of age, smoking-
status, disease stage, location of primary tumor, prior
treatment, and performance status were well balanced
between arms (P> .05).
Toxicity and Adherence
Of 91 patients in the 13-CRA arm, 77% received at least
1 year and 52% received 2 years of treatment. Of 85
patients in the placebo arm, 82% and 67% completed 1
year and 2 years of treatment, respectively (P5 .45 and
P5 .045 for the comparison at 1 year and 2 years between
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arms, respectively). The main reasons for premature treat-
ment discontinuation in both arms were patient with-
drawal (21% [18 of 86 patients] in the 13-CRA arm; 10%
[8 of 80 patients] in the placebo arm; P5 .06) and toxic-
ity (9% [8 of 86 patients] in the 13-CRA arm; 4% [3 of
80 patients] in the placebo arm; P5 .21).
All patients who received protocol treatment were
included in the toxicity analysis regardless of eligibility
(n5 184). There were 2 deaths (1 cardiac arrest on 13-
CRA, 1 infection on placebo). Table 2 summarizes 13-
CRA–related toxicities (for the grading scale, see the
online supporting information). Most common grade 3
and 4 13-CRA–related toxicity was serum triglycerides
>100% above baseline (11 in the 13-CRA arm; 8 in the
placebo arm; P5 .63). Comparisons of other 13-CRA–
related toxicities (grade 3) revealed no significant differ-
ences between arms. However, when we compared grade
1 toxicities between arms, more adverse events were
observed in the 13-CRA arm with respect to skin toxicity
(38% vs 21%; P5 .02), cheilitis (23% vs 5%; P5 .001),
and nausea (10% vs 1%; P5 .02).
With respect to treatment-related toxic events
recorded based on Common Toxicity Criteria, most
events were grade 1 or 2 (75% in the 13-CRA arm; 79%
in the placebo arm; data not shown). Seventeen patients
(18%) in the 13-CRA arm experienced grade 3 toxic-
ities, compared with 12 patients (13%) in the placebo
arm (P5 .42). The most common grade 3 toxic events
were neuroclinical (headache, altered consciousness, inco-
ordination/involuntary movements; 4 in the 13-CRA
arm; 3 in the placebo arm), arthralgia (3 in the 13-CRA
arm; 0 in the placebo arm), skin (3 in the 13-CRA arm;
1 in the placebo arm), and cardiac (2 in the 13-CRA arm;
2 in the placebo arm).
Efficacy
A primary endpoint was the number of SPTs. Table 3 lists
SPTs by site and treatment arm. Of 45 patients who expe-
rienced SPTs, the most common sites were the head and
neck (n5 11) and lungs (n5 10). No significant differ-
ences were observed in the number of SPTs (22 of 91
Figure 1. This is a Consolidated Standards of Reporting Trials (CONSORT) diagram of the current study. CRA indicates 13-cis reti-
noic acid.
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patients in the 13-CRA arm vs 23 of 85 in the placebo
arm; P5 .73).
The TSP was another primary endpoint. Table 4
details the cumulative incidence of SPT by treatment arm.
The 1-year, 3-year, 5-year, 10-year, and 15-year cumula-
tive SPT rates for patients in the 13-CRA arm were 0.04,
0.14, 0.16, 0.18, and 0.21, respectively, compared with
0.04, 0.08, 0.18, 0.23, and 0.28 in the placebo arm.
(P5 .61), exhibiting no significant difference between
arms. This conclusion holds with a competing risk regres-
sion analysis (hazard ratio [HR] for 13-CRA/placebo,
0.86; 95% CI, 0.48-1.54; P5 .61). Because the eligibility
criterion of completion of primary therapy with surgery
and/or radiation was relaxed from within 35 days to
within 730 days before randomization during study
accrual, a secondary analysis was performed on the TSP
measured from the completion of primary therapy
(instead of from randomization). Again, no significant
benefit in the TSP was observed in patients who were
receiving 13-CRA (HR, 0.85; 95% CI, 0.47-1.52;
P5 .58).
A secondary endpoint was OS. The 1-year, 3-year,
5-year, 10-year, and 15-year OS rates for patients in the
13-CRA arm were 0.99, 0.90, 0.79, 0.60, and 0.49,
respectively, compared with 0.96, 0.91, 0.82, 0.48, and
0.31, respectively, in the placebo arm. With a median 16
years of follow-up, the 2-sided log-rank test yielded a P
value of .14, with a trend toward improved survival for
the 13-CRA arm (median, 14.9 vs 9.8 years; HR, 0.75;
95%CI, 0.51-1.10; P5 .14) (see Fig. 2B).
Subset analyses were performed to compare treat-
ment effect (13-CRA vs placebo) within each subgroup
stratified by sex, race, tumor site region, disease stage,
ECOG PS, prior treatment, and smoking status. The
analyses demonstrated no significant differences in the
TSP between arms in each subset. Figure 2C summarizes
these results in a forest plot. The forest plot in Figure 2D
illustrates the HR for death along with the corresponding
95% CI. Although it was not significant (P5 .065), there
was a trend toward improved OS among patients who
underwent surgery alone for their index tumor (n5 26;
HR, 0.50; P5 .057), women (n5 39; HR, 0.44;
P5 .065), and never/former smokers (n5 129) on low-
dose 13-CRA (P5 .055).
Multivariable Cox proportional-hazards and
competing-risk regression models were fit to determine
prognostic factors for OS and TSP, respectively. Covari-
ates included the treatment, patient, and disease charac-
teristics listed in Table 1. Only age and smoking history at
entry were identified as significant in the OS model.
When controlled for other factors, the HRs for death
comparing never-smokers versus current smokers and for-
mer smokers versus current smokers were 0.05 (95% CI,
0.01-0.36; P5 .003) and 0.26 (95% CI, 0.17-0.39;
P< .0001), respectively. For every 1-year increase in age,
the risk of death increased by 5% (95% CI, 1.03-1.07;
P< .0001). With respect to the TSP, no factor achieved
statistical significance (all P> .05).
To ensure that we were evaluating the impact of 13-
CRA on the development of new primaries alone, we con-
ducted a second analysis excluding patients whose SPT
occurred during the 6 months after randomization, antici-
pating that some patients might have had a subclinical
SPT at initial diagnosis. With this criterion, 171 patients
were included (2 assigned to 13-CRA and 3 assigned to











Age: Median [min, max], y 60 [36, 86] 62 [30, 80] .59
Smoking history .76
Never smoked 8 (9) 6 (7)
Smoked previously 57 (63) 58 (68)
Current smoker 26 (29) 21 (25)
Disease site .74
Oral cavity 29 (32) 31 (37)
Oropharynx 11 (12) 8 (10)
Larynx 51 (56) 44 (53)
Unknown 0 (0) 2
Sex .47
Men 73 (80) 64 (75)
Women 18 (20) 21 (25)
Stage .33
I 64 (70) 51 (63)
II 27 (30) 30 (37)
Unknown 0 4
Prior treatment .63
Radiotherapy 46 (52) 40 (48)
Surgery 26 (29) 30 (36)
Combined 17 (19) 13 (16)
Unknown 2 2
FU smoking status 1.00
No smoking after baseline 57 (64) 54 (65)
Smoking after baseline 32 (36) 29 (35)
Unknown 2 2
ECOG PS .67
0 78 (87) 70 (84)
1 12 (13) 13 (16)
Unknown 1 2
NCI race .04
White 75 (82) 79 (93)
Nonwhite 16 (18) 6 (7)
Abbreviations: 13-CRA, 13-cis retinoic acid; ECOG PS, Eastern Coopera-
tive Oncology Group performance status; FU, follow-up; max, maximum;
min, minimum; NCI, National Cancer Institute.
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placebo were excluded). The original conclusions regard-
ing the effect of 13-CRA on the number of SPTs, the
TSP, and OS held true (data not shown).
Enrollment on this study predated testing of oro-
pharynx tumors for human papillomavirus (HPV) status.
We used oropharyngeal tumors as a surrogate for
HPV-associated disease, although the proportion of
HPV-associated cancers in the oropharynx was likely
lower at the time this trial accrued. In this small subset
(n5 19), there were no significant associations between
region and SPT (24% in nonoropharynx vs 42% in oro-
pharynx sites; P5 .10).
DISCUSSION
We report a long-term, phase 3, intervention trial that
studied low-dose isotretinoin for benefit and tolerability
in patients who received treatment for early stage
SCCHN. Our findings did not confirm those from the
pivotal MD Anderson Cancer Center trial, in which high-
dose, short-term isotretinoin was received by patients
with stage I through IV SCCHN.9,10 There were no sta-
tistically significant benefits in either OS or SPT. How-
ever, compliance with treatment at 1 year was greater in
our study (77% vs 67% in the high-dose trial), presum-
ably because of decreased toxicities with the lower dose.
Our findings mirror those of Khuri et al12 as well as find-
ings from a large European trial reported in 2000.19
Stratification of results separately by prior treatment,
sex, and smoking status revealed a trend toward improved
OS for the 13-CRA arm in patients who underwent with
surgery alone, women, and never/former smokers. Statis-
tical significance was not achieved in the 13-CRA arm for
women, possibly because of the small size of this subgroup
(n5 39). This also was confounded by the finding that
TABLE 2. Incidence of Grade 1 through 4 13-Cis Retinoic Acid (13-CRA) Toxicities According to the 13-CRA
Grading Scale
Incidence: No. of Patients
13-CRA, N5 92 Placebo, N5 92
Gradea Gradea
Toxicity 1 2 3 4 1 2 3 4
Skin 32 2 1 — 15 3 1 —
Cheilitis 17 4 — — 4 1 — —
Conjunctivitis — 1 — — — — — —
Epistaxis 1 — — — — — — —
Hair 4 — — — 4 — — —
Nausea 8 1 — — 1 — — —
Diarrhea 5 — — — 3 — — —
Neurologic, headache 7 3 1 — 5 1 —
Reproductive function 1 1 — — — — — —
Bladder 1 — — — — — — —
Musculoskeletal 5 7 3 — 2 5 1 1
Fatigue 11 4 2 — 7 2 0 1
Liver 16 2 — — 13 1 1 —
Serum cholesterol 18 9 — — 14 8 1 —
Serum triglycerides 4 47 11 — 14 32 8 —
HDL cholesterol 23 12 — — 12 10 — —
Abbreviations: 13-CRA, 13-cis retinoic acid; HDL, High-density lipoprotein.
a For further details, see online supporting information.
TABLE 3. Incidence of Second Primary Cancers by
Site and Treatment
Treatment: No. of Patients
Second Primary
Site 13-CRA Placebo Total
Breast 1 2 3
Esophagus 0 1 1
Anal canal 0 1 1
Colorectal 0 3 3
Head and neck 7 4 11
Brain tumor 1 0 1
B-cell lymphoma 1 0 1
Lung 6 4 10
Melanoma 0 1 1
Nonmelanoma skin cancer 2 4 6
Endometrium, uterine corpus 1 0 1
Bladder, urinary tract 1 1 2
Prostate 1 2 3
Other gynecologic site 1 0 1
Total 22 23 45
Abbreviation: 13-CRA, 13-cis retinoic acid.
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79% of these 39 patients were never/former smokers.
Because a similar proportion of male patients (72%) were
never/former smokers but no 13-CRA benefit on OS was
noted, it is unlikely that the trend of a 13-CRA benefit for
women is because of the effect of smoking status alone.
Khuri and colleagues12 enrolled a larger cohort of women
(n5 250) with early stage SCCHN but did not present
an analysis of benefit from low-dose isotretinoin in them.
Furthermore, a trend toward a survival benefit for the
never/former smoking group indicates that this group
merits further testing, and there may be a role for chemo-
prevention in the current generation of tobacco-cessation
studies.
Patients who enrolled at different institutions had
follow-up for disease assessment for differing periods after
the completion of therapy, leading to the possibility of
underestimating rate the of SPT. To further account for
patients who died without an SPT reported, we have cen-
sored the TSP at the point of last contact and considered
death as a competing risk in our analysis to accurately
determine SPT incidence and effect estimates.
It is possible that the lower dose of isotretinoin used
in the C0590 trial diminished the benefit previously
observed with higher doses of the drug, either when used
alone9,10 or when used in combination with interferon a
and vitamin E in patients with locally advanced
SCCHN.20,21 It is also possible that excluding the locally
advanced subgroup of patients mitigated a likely benefit,
because this would be the subset with the highest risk of
recurrence. Another possibility for failing to detect any
benefit is the observed higher cumulative incidence rate of
SPT in our study (21% for 13-CRA and 28% for placebo
at 15 years) than expected (10% vs 20%, respectively,
based on a cure rate model), leading to less power to detect





Total No. 1 Year 3 Years 5 Years 10 Years 15 Years
HR (95% CI):
13-CRA/Placeboa Wald Pa
SPT 13-CRA 22/91 0.04 0.14 0.16 0.18 0.21 0.86 (0.48-1.54) . 61
Placebo 22/85 0.04 0.08 0.18 0.23 0.28
OS 13-CRA 53/91 0.99 0.90 0.79 0.60 0.49 0.75 (0.51-1.10) .14
Placebo 55/85 0.96 0.91 0.82 0.48 0.31
Abbreviations: 13-CRA, 13-cis retinoic acid; CI, confidence interval; HR, hazard ratio; OS, overall survival; SPT, second primary tumor.
a These data are from the univariate analysis.
Figure 2. Charts illustrate (A) the cumulative incidence of second primary tumor by treatment arm and (B) Kaplan-Meier curves
for overall survival by treatment arm. Forest plots illustrate the treatment effect on (C) time to second primary and (D) overall
survival for all analyzable patients (n5 176). Note that the size of the squares is inversely proportional to the variance of the log
hazard ratio (HR) (small squares correspond to large variances). Bars represent 95% confidence intervals (CIs). CRA indicates 13-
cis retinoic acid; ECOG PS, Eastern Cooperative Oncology Group performance status.
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Figure 2. Continued
Original Article
4660 Cancer December 1, 2017
the difference. Although our small sample size (because of
early termination) might have further limited power to
detect a significant difference in endpoints between the
arms, our findings follow those from the largest patient
sample enrolled in a similar study led by the MD Ander-
son Cancer Centerm12 and we can conclusively rest this
question of low-dose vitamin A analogues having a sub-
stantive chemopreventive role in patients with early stage
SCCHN.
These results are reported in an era of personalized
medicine, and the lack of molecular characterization of
patients’ tumors is a limitation in the study design. A
wealth of data pertaining to driver mutations in SCCHN
has emerged from the Cancer Genome Atlas.22 Final
results of the EPOC (Erlotinib Prevention of Oral Can-
cer) trial are also reported, and that study validated the use
of loss of heterozygosity as a prognostic biomarker.23 It is
imperative therefore, that future prevention efforts factor
in both prognostic (smoking, HPV status, and loss of het-
erozygosity) and predictive molecular markers to optimize
responses and resources.
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